<DOC>
	<DOCNO>NCT03048578</DOCNO>
	<brief_summary>This randomize , double-blinded , placebo-controlled trial liraglutide versus placebo follow-up period 12 month patient least 18 month follow Roux-en-Y gastric bypass ( RYGB ) experience weight regain . This study ass efficacy liraglutide improve cardiometabolic risk profile ( indicated serum lipid , HbA1c , waist circumference ) quality life ( assess PHQ-9 ( Patient Health Questionnaire ) , versus placebo patient least 18 month follow RYGB experience weight regain well safety liraglutide patient population .</brief_summary>
	<brief_title>Clinical Efficacy Safety Using 3.0mg Liraglutide Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery</brief_title>
	<detailed_description>The specific aim study : - To evaluate effect liraglutide body weight loss patient experience weight regain follow RYGB . - To evaluate effect liraglutide cardiometabolic risk quality life patient experience weight regain follow RYGB . - To evaluate safety liraglutide post-RYGB subject . - To evaluate change obesity-related comorbid condition patient experience weight regain follow RYGB .</detailed_description>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>≥18 month statuspost RYGB BMI 27 kg/m2 great presence least one weightrelated comorbid condition BMI 30 kg/m2 great Regain ≥10 % maximum TBWL postRYGB Ability provide inform consent trialrelated activity Express willingness follow protocol requirement Pregnancy time enrollment Intention become pregnant breast feed next 12 month Females childbearing potential use adequate contraceptive method Presence acute psychiatric problem immaturity would compromise cooperation study protocol Presence biliary disease Known suspect allergy liraglutide product component Personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome type 2 History pancreatitis History alcoholism History Type 1 DM ( Diabetes Mellitus ) History previous bariatric surgery RYGB except h/o LAGB band removal . &gt; 10 year statuspost RYGB &lt; 25 % TBWL postRYGB weight nadir &gt; 50 % postoperative TBWL time screen Simultaneous use weight loss medication Use insulin time enrollment Current use GLP1 agonist medication History take GLP1 agonist medication Participation another ongoing clinical study Conditions , opinion principal investigator , may jeopardize patient 's wellbeing and/or soundness clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Roux-en-Y gastric bypass ( RYGB )</keyword>
</DOC>